Page 26 - 2021_10-Haematologica-web

S.R. McCurdy and S.M. Luger
>/=60 years old. Am J Hematol. 2015;90(7):
639-646.
96.Oh SB, Park SW, Chung JS, et al.
Therapeutic decision-making in elderly patients with acute myeloid leukemia: con- ventional intensive chemotherapy versus hypomethylating agent therapy. Ann Hematol. 2017;96(11):1801-1809.
97. van der Helm LH, Scheepers ER, Veeger NJ, et al. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hematol Oncol. 2013;6:29.
98. van der Helm LH, Veeger NJ, Kooy M, et al. Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts. Leuk Res. 2013;37(8):877-882.
99. Lao Z, Yiu R, Wong GC, Ho A. Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complica- tions but similar survival compared with intensive chemotherapy. Asia Pac J Clin Oncol. 2015;11(1):54-61.
100.Choi EJ, Lee JH, Park HS, et al. Decitabine versus intensive chemotherapy for elderly patients with newly diagnosed acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2019;19(5):290-299.
101.Lubbert M, Bertz H, Muller MJ, Finke J. When azanucleoside treatment can be cura- tive: nonintensive bridging strategy before allografting in older patients with myelodys- plastic syndrome/acute myeloid leukemia. J Clin Oncol. 2013;31(6):822-823.
102. Ferrara F, Barosi G, Venditti A, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013; 27(5):997-999.
103. McCurdy SR, Gier SH, Babushok DV, et al. Fried frailty phenotype predicts mortality for newly diagnosed older patients with acute myeloid leukemia or high risk myelodysplastic syndrome. Blood. 2019;134 (Suppl 1):2209.
104. Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for pre- diction of outcomes. Lancet. 2010;376 (9757):2000-2008.
105.Kantarjian H, Ravandi F, O'Brien S, et al. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010;116(22):4422-4429.
106. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemother- apy for acute myelogenous leukemia. Blood. 2013;121(21):4287-4294.
107. Ghosn M, Ibrahim T, El Rassy E, Nassani N, Ghanem S, Assi T. Abridged geriatric assess- ment is a better predictor of overall survival than the Karnofsky Performance Scale and Physical Performance Test in elderly patients with cancer. J Geriatr Oncol. 2017;8(2):128- 132.
108. Bonanad S, De la Rubia J, Gironella M, et al. Development and psychometric validation of a brief comprehensive health status assessment scale in older patients with hematological malignancies: the GAH Scale. J Geriatr Oncol. 2015;6(5):353-361.
109. Magnuson A, Lemelman T, Pandya C, et al. Geriatric assessment with management intervention in older adults with cancer: a randomized pilot study. Support Care Cancer. 2018;26(2):605-613.
110. Elliot K, Tooze JA, Geller R, et al. The prog- nostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML). Leuk Res. 2014;38(10): 1184-1190.
111.Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
112.Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classify- ing prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
113.Etienne A, Esterni B, Charbonnier A, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109(7): 1376-1383.
114.
Sorror ML, Storer BE, Fathi AT, et al. Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality. JAMA Oncol. 2017;3(12):1675-1682.
2554
haematologica | 2021; 106(10)